Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents
Key facts
- Who runs it
- King's College London
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 25 people enrolled
- Started
- 1 Oct 2018
- Ended
- 7 Sept 2024
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Lisdexamfetamine dimesylate
- Guanfacine Extended Release Oral Tablet
- Placebo
- Record updated
- 12 August 2026
Who can take part
- Age
- 8 years to 20 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Age range: 8-20 years
- Medication-naïve or non-medicated for two weeks or on stimulant medication, and willing to take the medication off for 48 hours before scans
- Meeting DSM-5 diagnosis of ADHD
- Score above clinical cut-off on the ADHD module of the Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS) (Kaufman et al., 1997)
- Score above clinical cut-off for ADHD on the short forms of the Conners Parent Rating Scales, CPRS (Conners et al., 2008)
- Score above cut-off on the ADHD Rating Scale, ADHD-RS (DuPaul, et al., 1998)
- IQ > 70 as tested on the WASI-II (Wechsler et al., 1999)
- Mood and depression symptoms will be allowed as long as they are not the primary diagnosis
Who cannot take part
- Contraindication to MRI. i.e., previous implantation of metallic material, pacemaker, implanted medication pumps, neural stimulators, claustrophobia
- Comorbidity with schizophrenia, bipolar disorder, learning disability, OCD, severe depression with current suicidal behaviour (as assessed by a clinical interview)
- Neurological problems, i.e. a history of severe neurological illness, e.g. brain tumour, epilepsy or a history of symptomatic seizures, polyneuropathy etc
- Other illness (cardiovascular, renal, hepatic, metabolic) that would impact the data integrity or safety of the subject (i.e. contraindicated to any of the treatments) as determined by the investigators
- Contraindications for LISDEX and GXR use (i.e. advanced arteriosclerosis, agitated states, hyperexcitability, hyperthyroidism, moderate or severe hypertension, symptomatic cardiovascular disease)
- IQ < 70 (Wechsler et al., 1999)
- Substance abuse history
- Unable to give informed assent or consent in the case of the parent
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is not a clinical trial. The aim of this study is to understand the mechanism of action of two recently licensed drugs for ADHD on brain function. The investigators will compare the brain activation changes elicited by Guanfacine extended release (GXR; a non-stimulant drug) with the brain activation changes elicited by Lisdexamfetamine (LISDEX; a stimulant drug) and by placebo in 20 drug-free patients with ADHD using functional Magnetic Resonance Imaging (fMRI). For this purpose the investigators intend to scan participants during their performance of tasks of attention, working memory, and inhibition, which the investigators know from previous studies to elicit abnormal brain activation patterns in ADHD patients (Rubia et al., 2005; Smith et al., 2006).
The 3 groups in the trial
- Lisdexamfetamine - PlaceboExisting treatment, for comparison
Treatment: Lisdexamfetamine dimesylate and Placebo
- Guanfacine - PlaceboExisting treatment, for comparison
Treatment: Guanfacine Extended Release Oral Tablet and Placebo
- Lisdexamfetamine - GuanfacineTreatment being tested
Treatment: Lisdexamfetamine dimesylate and Guanfacine Extended Release Oral Tablet
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Experimental fMRI Study on the Comparison of the Brain Function Effects of a Single Dose of Guanfacine and Lisdexamfetamine Relative to Placebo in Children and Adolescents With ADHD.
- Publications
- Record updated
- 12 August 2026